Is NF-kappaB a useful therapeutic target in rheumatoid arthritis?
There is increasing evidence that NF-kappaB is a major, if not the major transcription factor regulating inflammation and immunity. While this implies that blocking NF-kappaB might be therapeutically beneficial, it raises clear questions regarding the balance between efficacy and safety. In this brief review we discuss the effects of NF-kappaB blockade in rheumatoid arthritis, inflammation and immunity, and consider possible therapeutic targets within the NF-kappaB family.
Feldmann
M
M
Kennedy Institute of Rheumatology Division, Faculty of Medicine, Charing Cross Hospital Campus, Arthritis Research Campaign Building, 1 Aspenlea Road, London W6 8LH, UK. mfeldmann@ic.ac.uk
Andreakos
E
E
Smith
C
C
Bondeson
J
J
Yoshimura
S
S
Kiriakidis
S
S
Monaco
C
C
Gasparini
C
C
Sacre
S
S
Lundberg
A
A
Paleolog
E
E
Horwood
N J
NJ
Brennan
F M
FM
Foxwell
B M J
BM
D000256:Adenoviridae / Q000235:genetics; D017951:Antigen Presentation; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000628:therapy*; D018929:Cell Culture Techniques; D003713:Dendritic Cells / Q000276:immunology; D005822:Genetic Vectors; D006801:Humans; D020672:I-kappa B Proteins / Q000235:genetics; D007111:Immunity, Cellular; D007959:Lymphocyte Culture Test, Mixed; D016328:NF-kappa B / Q000037:antagonists & inhibitors* / Q000502:physiology; D013583:Synovial Membrane / Q000276:immunology
D020672:I-kappa B Proteins; D016328:NF-kappa B